Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of norucholic acid in primary sclerosing cholangitis
ISRCTN58756615Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Occurrence of adverse events during treatment and Occurrence of adverse events of special interest. Started Mar 2025; status: active, not recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on ISRCTN58756615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58756615.